Search - tctmd.com

Displaying 61 - 80 of 103

Sort: Relevancy | Date

News Conference News ESC 2020

EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class

Michael O'Riordan

August 29, 2020

News Conference News ESC 2020

Rhythm Control Cuts First CV Events in Early Atrial Fibrillation: EAST-AFNET 4

Shelley Wood

August 29, 2020

News Conference News ESC 2020

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

Michael O'Riordan

August 28, 2020

News Conference News ESC 2019

GARFIELD-AF Analysis Digs Into Impact of Bleeding in Newly Diagnosed A-fib

Todd Neale

September 12, 2019

News Conference News ESC 2019

Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis

Yael L. Maxwell

September 12, 2019

News Conference News ESC 2019

GRACE Risk Tool Fails to Increase Use of Guideline-Based Care After ACS: AGRIS

Yael L. Maxwell

September 10, 2019

News Conference News ESC 2019

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

Michael O'Riordan

September 05, 2019

News Conference News ESC 2019

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

Todd Neale

September 03, 2019

News Conference News ESC 2019

CLARIFY at 5 Years: Angina Predictive of MI/CV Death Only in Prior MI Patients

Shelley Wood

September 03, 2019

News Conference News ESC 2019

CONDI-2/ERIC-PPCI Puts the Kibosh on Ischemic Conditioning in STEMI

Yael L. Maxwell

September 01, 2019

$Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction Primary results of the PARAGON-HF trial$

Presentation ESC 2019

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Primary Results of the PARAGON-HF Trial

Presenter: Scott D. Solomon

September 01, 2019

News Conference News ESC 2019

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

Shelley Wood

September 01, 2019

News Conference News ESC 2019

PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen

Todd Neale

September 01, 2019

News Conference News ESC 2019

Increasing Oral Anticoagulation Use Tied to Less Ischemic Stroke in A-fib Patients in Italy

Todd Neale

August 31, 2019

News Conference News ESC 2019

New ‘Chronic Coronary Syndrome’ Guidelines Stress There’s Nothing Stable About CAD

Shelley Wood

August 31, 2019

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Conference News ESC 2018

New ESC/EACTS Revascularization Guidelines Make Room for Radial First, STICH, and DES for All

Michael O'Riordan

August 29, 2018

Medically Ill Pa+ent Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk (MARINER) Trial: Primary Results

Presentation ESC 2018

Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk (MARINER) Trial: Primary Results

Presenter: Alex C. Spyropoulos

August 27, 2018

News Conference News ESC 2018

COMMANDER HF: Low-Dose Rivaroxaban Flops in Heart Failure

Todd Neale

August 27, 2018

News Conference News ESC 2018

Omega-3 Fatty Acids Fail to Reduce CVD Events in Diabetic Patients: ASCEND

Michael O'Riordan

August 26, 2018

Advertisement

EXPLORER-HCM: Mavacamten Improves Exercise Capacity and Functional Class

Rhythm Control Cuts First CV Events in Early Atrial Fibrillation: EAST-AFNET 4

EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF

GARFIELD-AF Analysis Digs Into Impact of Bleeding in Newly Diagnosed A-fib

Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis

GRACE Risk Tool Fails to Increase Use of Guideline-Based Care After ACS: AGRIS

New ESC Diabetes Guidelines Focus on CVD Prevention, New Drug Classes, and Low LDL

For A-fib/PCI Combo, Edoxaban Matches VKA but Not Superior: ENTRUST-AF PCI

CLARIFY at 5 Years: Angina Predictive of MI/CV Death Only in Prior MI Patients

CONDI-2/ERIC-PPCI Puts the Kibosh on Ischemic Conditioning in STEMI

Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction Primary Results of the PARAGON-HF Trial

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

PARAGON-HF Misses Primary Endpoint, but Hints of Benefit Seen

Increasing Oral Anticoagulation Use Tied to Less Ischemic Stroke in A-fib Patients in Italy

New ‘Chronic Coronary Syndrome’ Guidelines Stress There’s Nothing Stable About CAD

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

New ESC/EACTS Revascularization Guidelines Make Room for Radial First, STICH, and DES for All

Medically Ill Patient Assessment of Rivaroxaban Versus Placebo IN Reducing Post-Discharge Venous Thrombo-Embolism Risk (MARINER) Trial: Primary Results

COMMANDER HF: Low-Dose Rivaroxaban Flops in Heart Failure

Omega-3 Fatty Acids Fail to Reduce CVD Events in Diabetic Patients: ASCEND

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content